Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05909332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05909332 · ClinicalTrials.gov record · last posted 2026-01-21

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Name: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) — clinical trial record (NCT05909332)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorFudan University

Started2023-06-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2023-06-11; most recent amendment 2026-01-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-07-09

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT05909332
Lead Sponsor	Fudan University
Conditions	Breast Cancer, Triple Negative Breast Cancer
Enrollment	764 participants
Start Date	2023-06-20
Primary Completion	2029-05-30 (estimated)
Study Completion	2031-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-21